Mechanical circulatory support for cardiac amyloidosis

Cardiac amyloidosis, typically from abnormal deposition of AL or ATTR amyloid protein, can result in heart failure requiring transplantation (HTx). The role of mechanical circulatory support (MCS) is not well‐established. The purpose of this study was to present our experience with MCS in patients with cardiac amyloidosis.

[1]  W. Tang.  Faculty Opinions recommendation of Mechanical circulatory support for cardiac amyloidosis. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  Richard G. Smith,et al.  Interagency registry for mechanically assisted circulatory support report on the total artificial heart. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[4]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[5]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[6]  S. Solomon,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[7]  Andre H Crepaldi,et al.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma , 2017, The New England journal of medicine.

[8]  Snehal R. Patel,et al.  Outcomes of Restrictive and Hypertrophic Cardiomyopathies After LVAD: An INTERMACS Analysis. , 2017, Journal of cardiac failure.

[9]  H. Katus,et al.  Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  S. Wong,et al.  Frailty and Clinical Outcomes in Advanced Heart Failure Patients Undergoing Left Ventricular Assist Device Implantation: A Systematic Review and Meta-analysis. , 2017, Journal of the American Medical Directors Association.

[11]  L. Allen,et al.  Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support , 2017, ASAIO journal.

[12]  Keshav R. Nayak,et al.  Total Artificial Heart Implantation as a Bridge to Heart Transplantation in an Active Duty Service Member With Amyloid Cardiomyopathy. , 2017, Military medicine.

[13]  M. Guglin,et al.  Heart transplantation in cardiac amyloidosis , 2017, Heart Failure Reviews.

[14]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[15]  Y. Gerber,et al.  Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  A. Dispenzieri,et al.  Left ventricular device implantation for advanced cardiac amyloidosis. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  M. Dimopoulos,et al.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. , 2013, Blood.

[18]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[19]  Charles M. Miller,et al.  Combined heart and liver transplantation: the Cleveland Clinic experience. , 2013, The Annals of thoracic surgery.